BOSTON — Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. to advance antisense therapeutics using Alloy’s proprietary AntiClastic ASO platform, the companies said.
Under the agreement, Biogen will apply the platform across multiple undisclosed targets, while Alloy will receive an upfront payment and remain eligible for milestone payments and tiered royalties tied to any resulting products.
The partnership builds on an existing relationship between the two companies, including Biogen’s prior use of Alloy’s AI-enabled transgenic mouse platform.
Alloy’s AntiClastic platform is designed to improve the performance of antisense oligonucleotide drugs by enhancing their ability to reach intracellular RNA targets. The technology aims to address longstanding challenges in the field, including limited biodistribution and suboptimal therapeutic index, which have constrained the effectiveness of earlier antisense approaches.
“Biogen has built an extraordinary reputation for scientific leadership and for translating breakthrough research into impactful therapies,” said Errik Anderson, CEO and founder of Alloy Therapeutics. “We value our long-standing relationship and are honored to support their world-class teams with access to our AntiClastic ASO platform and broader technology ecosystem, helping enable the continued pursuit of innovative treatments that have the potential to change patients’ lives.”
Biogen said the collaboration aligns with its strategy of exploring new modalities to address complex diseases.
“This collaboration reflects Biogen’s commitment to pushing the boundaries of scientific innovation and exploring novel approaches to address complex diseases,” said Jane Grogan, Ph.D., executive vice president and head of research at Biogen. “Partnering with Alloy allows us to expand our research strategies and continue advancing programs with the potential to benefit patients worldwide.”
Alloy said its broader drug discovery ecosystem integrates computational and AI-driven tools alongside its experimental platforms to accelerate the development of new therapeutics.
